Morgan Stanley raised the firm’s price target on Donaldson (DCI) to $69 from $65 and keeps an Underweight rating on the shares. The firm updated estimates and is rolling forward its valuation to FY26 and increasing share repurchase expectations, but remains Underweight following fiscal Q3 reporting as it continues to see risk to the Life Sciences growth strategy, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCI:
- Hold Rating on Donaldson Company Amid Bioprocessing Challenges and Market Uncertainties
- Donaldson price target raised to $78 from $76 at Baird
- Donaldson’s Business at Risk: How International Tariffs Could Impact Operations and Competitiveness
- Morning Movers: Signet Jewelers and Dollar General surge following Q1 results
- Donaldson Company Appoints New COO Amidst Strong Q3 Results